Key Highlights
- Hylton Kalvaria appointed as SVP of Life Sciences at Helix, bringing vast experience from the healthcare data sector.
- Kalvaria to spearhead partnerships with life sciences companies, leveraging Helix’s unique clinico-genomic datasets.
- Helix continues to support the development of personalized therapies, with significant advancements in 2023 and early 2024.
Source: Business Wire
Notable Quotes
- “We’re thrilled with the momentum we’ve seen in 2023 and the start of 2024… Strengthening our leadership team with someone as talented and passionate as Hylton only further positions Helix to ensure the power of genomics is used to improve healthcare outcomes on the largest possible scale.” – James Lu, MD, Ph.D., CEO and co-founder at Helix
- “I’m proud to be part of a company doing meaningful work that has the potential to affect positive change for all stakeholders in the healthcare ecosystem.” – Hylton Kalvaria, SVP of Life Sciences at Helix
SoHC's Take
Helix’s recent move to bring on Hylton Kalvaria as Senior Vice President of Life Sciences underscores the company’s dedication to advancing the field of genomics through strategic partnerships and leveraging their extensive clinico-genomic datasets. This appointment not only reinforces Helix’s position as a leader in population genomics but also highlights the growing importance of genetic approaches in the development of new drugs. The collaboration between Helix and its life sciences partners is poised to accelerate the discovery and commercialization of innovative, personalized therapies, ultimately aiming to improve healthcare outcomes on a broad scale.
